Bayesian Capital Management LP purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,200 shares of the biotechnology company’s stock, valued at approximately $472,000.

Several other large investors also recently made changes to their positions in BMRN. Jennison Associates LLC increased its holdings in shares of BioMarin Pharmaceutical by 33.8% during the second quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock worth $1,202,709,000 after buying an additional 3,348,168 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of BioMarin Pharmaceutical by 63.7% during the second quarter. TIAA CREF Investment Management LLC now owns 2,251,011 shares of the biotechnology company’s stock worth $204,437,000 after buying an additional 875,686 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of BioMarin Pharmaceutical by 10.5% during the first quarter. Primecap Management Co. CA now owns 8,712,268 shares of the biotechnology company’s stock worth $764,763,000 after buying an additional 826,320 shares in the last quarter. USS Investment Management Ltd increased its holdings in shares of BioMarin Pharmaceutical by 214.7% during the second quarter. USS Investment Management Ltd now owns 1,089,933 shares of the biotechnology company’s stock worth $98,988,000 after buying an additional 743,599 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 4.7% during the second quarter. Vanguard Group Inc. now owns 14,345,027 shares of the biotechnology company’s stock worth $1,302,816,000 after buying an additional 642,623 shares in the last quarter. Institutional investors own 97.46% of the company’s stock.

Several research analysts have recently issued reports on the stock. Jefferies Group LLC reiterated a “buy” rating and set a $116.00 price target on shares of BioMarin Pharmaceutical in a report on Tuesday, September 26th. Deutsche Bank AG restated a “buy” rating and issued a $119.00 price objective (up from $118.00) on shares of BioMarin Pharmaceutical in a report on Wednesday, August 9th. Wedbush restated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a report on Monday, August 7th. UBS AG restated a “neutral” rating and issued a $93.00 price objective (up from $92.00) on shares of BioMarin Pharmaceutical in a report on Thursday, August 3rd. Finally, Cowen and Company restated a “buy” rating on shares of BioMarin Pharmaceutical in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $109.09.

In related news, insider Henry J. Fuchs sold 15,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the transaction, the insider now owns 141,422 shares in the company, valued at $12,798,691. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $91.26, for a total transaction of $342,225.00. Following the transaction, the director now owns 19,660 shares in the company, valued at approximately $1,794,171.60. The disclosure for this sale can be found here. Insiders have sold 22,271 shares of company stock worth $2,034,220 in the last quarter. 2.50% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 93.07 on Friday. The company’s market cap is $16.31 billion. The stock’s 50 day moving average is $86.72 and its 200-day moving average is $89.48. BioMarin Pharmaceutical Inc. has a 52-week low of $78.42 and a 52-week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a negative net margin of 15.54% and a negative return on equity of 5.77%. The company had revenue of $317.50 million for the quarter, compared to analysts’ expectations of $311.41 million. During the same quarter in the previous year, the company earned ($2.61) earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 5.8% on a year-over-year basis. Equities research analysts predict that BioMarin Pharmaceutical Inc. will post ($0.71) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Bayesian Capital Management LP Purchases Shares of 5,200 BioMarin Pharmaceutical Inc. (BMRN)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/bayesian-capital-management-lp-purchases-shares-of-5200-biomarin-pharmaceutical-inc-bmrn/1601155.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.